Clinical manifestations and pathogenesis of syndromes associated with neuroblastic tumors

References:

[1] 王鹏程,董瑞.神经母细胞瘤4S期预后不良相关因素的研究进展[J].临床小儿外科杂志,2022,21(4):394-398.DOI:10.3760/cma.j.cn101785-202108053-019. Wang PC,Dong R.Research advances on poor prognostic factors of children with stage 4S neuroblastoma[J].DOI:10.3760/cma.j.cn101785-202108053-019.
[2] 张梅慧,姜大朋.先天性神经母细胞瘤发病机制与临床特点的研究进展[J].临床小儿外科杂志,2022,21(2):141-145.DOI:10.3760/cma.j.cn101785-202105045-008. Zhang MH,Jiang DP.Pathogenesis and clinical characteristics of congenital neuroblastoma[J].J Clin Ped Sur,2022,21(2):141-145.DOI:10.3760/cma.j.cn101785-202105045-008.
[3] Zeineldin M,Patel AG,Dyer MA.Neuroblastoma:when differentiation goes awry[J].Neuron,2022,110(18):2916-2928.DOI:10.1016/j.neuron.2022.07.012.
[4] Swift CC,Eklund MJ,Kraveka JM,et al.Updates in diagnosis,management,and treatment of neuroblastoma[J].Radiographics,2018,38(2):566-580.DOI:10.1148/rg.2018170132.
[5] Shimada H,Ambros IM,Dehner LP,et al.The international neuroblastoma pathology classification (the shimada system)[J].Cancer,1999,86(2):364-372.
[6] Mete O,Asa SL,Gill AJ,et al.Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas[J].Endocr Pathol,2022,33(1):90-114.DOI:10.1007/s12022-022-09704-6.
[7] Maris JM.Recent advances in neuroblastoma[J].N Engl J Med,2010,362(23):2202-2211.DOI:10.1056/NEJMra0804577.
[8] Zafar A,Wang W,Liu G,et al.Molecular targeting therapies for neuroblastoma:progress and challenges[J].Med Res Rev,2021,41(2):961-1021.DOI:10.1002/med.21750.
[9] Sznewajs A,Pon E,Matthay KK.Congenital malformation syndromes associated with peripheral neuroblastic tumors:a systematic review[J].Pediatr Blood Cancer,2019,66(10):e27901.DOI:10.1002/pbc.27901.
[10] Ma GM,Chow JS,Taylor GA.Review of paraneoplastic syndromes in children[J].Pediatr Radiol,2019,49(4):534-550.DOI:10.1007/s00247-019-04371-y.
[11] Sardi?a González C,Martínez Vivero C,López Castro J.Paraneoplastic syndromes review:the great forgotten ones[J].Crit Rev Oncol Hematol,2022,174:103676.DOI:10.1016/j.critrevonc.2022.103676.
[12] Rothenberg AB,Berdon WE,D’Angio GJ,et al.The association between neuroblastoma and opsoclonus-myoclonus syndrome:a historical review[J].Pediatr Radiol,2009,39(7):723-726.DOI:10.1007/s00247-009-1282-x.
[13] Kimura N,Yamamoto H,Okamoto H,et al.Multiple-hormone gene expression in ganglioneuroblastoma with watery diarrhea,hypokalemia,and achlorhydria syndrome[J].Cancer,1993,71(9):2841-2846.DOI:10.1002/1097-0142(19930501)71:9<2841::aid-cncr2820710927>3.0.co;2-z.
[14] Normann T,Havnen J,Mjolnerod O.Cushing’s syndrome in an infant associated with neuroblastoma in two ectopic adrenal glands[J].J Pediatr Surg,1971,6(2):169-175.DOI:10.1016/0022-3468(71)90313-7.
[15] Elzomor H,El Menawi S,Elawady H,et al.Neuroblastoma-associated opsoclonous myoclonous ataxia syndrome:profile and outcome report on 15 Egyptian patients[J].J Pediatr Hematol Oncol,2023,45(2):e194-e199.DOI:10.1097/MPH.0000000000002466.
[16] Bourgois B,Boman F,Nelken B,et al.Intractable diarrhoea revealing a neuroblastoma hypersecreting the vasoactive intestinal peptide[J].Arch Pediatr,2004,11(4):340-343.DOI:10.1016/j.arcped.2004.01.015.
[17] Rossor T,Yeh EA,Khakoo Y,et al.Diagnosis and management of Opsoclonus-Myoclonus-Ataxia syndrome in children:an international perspective[J].Neurol Neuroimmunol Neuroinflamm,2022,9(3):e1153.DOI:10.1212/NXI.0000000000001153.
[18] King PH,Redden D,Palmgren JS,et al.Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease[J].J Autoimmun,1999,13(4):435-443.DOI:10.1006/jaut.1999.0337.
[19] Mitchell WG,Blaes F.Cancer and autoimmunity:paraneoplastic neurological disorders associated with neuroblastic tumors[J].Semin Pediatr Neurol,2017,24(3):180-188.DOI:10.1016/j.spen.2017.08.011.
[20] Harvengt J,Gernay C,Mastouri M,et al.ROHHAD(NET) syndrome:systematic review of the clinical timeline and recommendations for diagnosis and prognosis[J].J Clin Endocrinol Metab,2020,105(7):dgaa247.DOI:10.1210/clinem/dgaa247.
[21] Giacomozzi C,Guaraldi F,Cambiaso P,et al.Anti-hypothalamus and anti-pituitary auto-antibodies in ROHHAD syndrome:additional evidence supporting an autoimmune etiopathogenesis[J].Horm Res Paediatr,2019,92(2):124-132.DOI:10.1159/000499163.
[22] Patwari PP,Wolfe LF.Rapid-onset obesity with hypothalamic dysfunction,hypoventilation,and autonomic dysregulation:review and update[J].Curr Opin Pediatr,2014,26(4):487-492.DOI:10.1097/MOP.0000000000000118.
[23] Hereditary cancer syndromes and risk assessment:ACOG Committee Opinion,number 793[J].Obstet Gynecol,2019,134(6):e143-e149.DOI:10.1097/AOG.0000000000003562.
[24] Fetahu IS,Taschner-Mandl S.Neuroblastoma and the epigenome[J].Cancer Metastasis Rev,2021,40(1):173-189.DOI:10.1007/s10555-020-09946-y.
[25] Qian LD,Yang S,Zhang SX,et al.Prediction of MYCN amplification,1p and 11q aberrations in pediatric neuroblastoma via pre-therapy 18F-FDG PET/CT radiomics[J].Front Med (Lausanne),2022,9:840777.DOI:10.3389/fmed.2022.840777.
[26] Sato TS,Handa A,Priya S,et al.Neurocristopathies:enigmatic appearances of neural crest cell-derived abnormalities[J].Radiographics,2019,39(7):2085-2102.DOI:10.1148/rg.2019190086.
[27] Kamihara J,Bourdeaut F,Foulkes WD,et al.Retinoblastoma and neuroblastoma predisposition and surveillance[J].Clin Cancer Res,2017,23(13):e98-e106.DOI:10.1158/1078-0432.CCR-17-0652.
[28] Vega-Lopez GA,Cerrizuela S,Tribulo C,et al.Neurocristopathies:new insights 150 years after the neural crest discovery[J].Dev Biol,2018,444(Suppl 1):S110-S143.DOI:10.1016/j.ydbio.2018.05.013.
[29] Shimada H,Ikegaki N.Neuroblastoma and neuroblastic tumors[M]//Furtado LV,Husain AN.Precision Molecular Pathology of Neoplastic Pediatric Diseases.Cham:Springer,2018:151-168.
[30] Berry-Kravis EM,Zhou LL,Rand CM,et al.Congenital central hypoventilation syndrome:PHOX2B mutations and phenotype[J].Am J Respir Crit Care Med,2006,174(10):1139-1144.DOI:10.1164/rccm.200602-305OC.
[31] Yang LQ,Ke XX,Xuan F,et al.PHOX2B is associated with neuroblastoma cell differentiation[J].Cancer Biother Radiopharm,2016,31(2):44-51.DOI:10.1089/cbr.2015.1952.
[32] Gross AM,Frone M,Gripp KW,et al.Advancing RAS/RASopathy therapies:an NCI-sponsored intramural and extramural collaboration for the study of RASopathies[J].Am J Med Genet A,2020,182(4):866-876.DOI:10.1002/ajmg.a.61485.
[33] Hebron KE,Hernandez ER,Yohe ME.The RASopathies:from pathogenetics to therapeutics[J].Dis Model Mech,2022,15(2):dmm049107.DOI:10.1242/dmm.049107.
[34] Rauen KA.Defining RASopathy[J].Dis Model Mech,2022,15(2):dmm049344.DOI:10.1242/dmm.049344.
[35] Riller Q,Rieux-Laucat F.RASopathies:from germline mutations to somatic and multigenic diseases[J].Biomed J,2021,44(4):422-432.DOI:10.1016/j.bj.2021.06.004.
[36] Mlakar V,Morel E,Mlakar SJ,et al.A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma[J].J Exp Clin Cancer Res,2021,40(1):189.DOI:10.1186/s13046-021-01967-x.
[37] Tartaglia M,Gelb BD.Noonan syndrome and related disorders:genetics and pathogenesis[J].Annu Rev Genomics Hum Genet,2005,6:45-68.DOI:10.1146/annurev.genom.6.080604.162305.
[38] Zhang XL,Dong ZW,Zhang C,et al.Critical role for GAB2 in neuroblastoma pathogenesis through the promotion of SHP2/MYCN cooperation[J].Cell Rep,2017,18(12):2932-2942.DOI:10.1016/j.celrep.2017.02.065.
[39] Ly KI,Blakeley JO.The diagnosis and management of neurofibromatosis type 1[J].Med Clin North Am,2019,103(6):1035-1054.DOI:10.1016/j.mcna.2019.07.004.
[40] Brioude F,Toutain A,Giabicani E,et al.Overgrowth syndromes-clinical and molecular aspects and tumour risk[J].Nat Rev Endocrinol,2019,15(5):299-311.DOI:10.1038/s41574-019-0180-z.
[41] Li YH,Donnelly CG,Rivera RM.Overgrowth syndrome[J].Vet Clin North Am Food Anim Pract,2019,35(2):265-276.DOI:10.1016/j.cvfa.2019.02.007.
[42] Harris JR,Fahrner JA.Disrupted epigenetics in the Sotos syndrome neurobehavioral phenotype[J].Curr Opin Psychiatry,2019,32(2):55-59.DOI:10.1097/YCO.0000000000000481.
[43] Manor J,Lalani SR.Overgrowth syndromes-evaluation,diagnosis,and management[J].Front Pediatr,2020,8:574857.DOI:10.3389/fped.2020.574857.
[44] Berdasco M,Ropero S,Setien F,et al.Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma[J].Proc Natl Acad Sci USA,2009,106(51):21830-21835.DOI:10.1073/pnas.0906831106.
[45] Fontana L,Tabano S,Maitz S,et al.Clinical and molecular diagnosis of Beckwith-Wiedemann syndrome with single-or multi-locus imprinting disturbance[J].Int J Mol Sci,2021,22(7):3445.DOI:10.3390/ijms22073445.
[46] Eggermann T,Maher ER,Kratz CP,et al.Molecular basis of Beckwith-Wiedemann syndrome spectrum with associated tumors and consequences for clinical practice[J].Cancers (Basel),2022,14(13):3083.DOI:10.3390/cancers14133083.
[47] Xu HL,Liu C,Yi M,et al.Neuroblastoma in a boy with Simpson-Golabi-Behmel syndrome[J].Chin J Pediatr,2022,60(3):244-245.DOI:10.3760/cma.j.cn112140-20210708-00565.